Autres langues Mendus AB

Actions

IMMU

SE0022239950

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm 18:00:00 06/10/2026			Varia. 5j.	Varia. 1 janv.
6,050 ^SEK	-1,63%		-6,92%	+8,04%

05/10	Mendus nomme un administrateur au poste de directeur des opérations	FW
01/10	Mendus présente des données à cinq ans pour le vididencel – premiers résultats dans la leucémie myéloïde chronique attendus au quatrième trimestre	FW

Autres langues

05/10	Mendus : utser Hans Preusting till Chief Operating Officer
05/10	Mendus announces appointment of Hans Preusting as Chief Operating Officer
01/10	Mendus announces presentation of updated ADVANCE II data and VITAL-CML progress
16/09	Mendus Launches Early-stage Trial for Acute Myeloid Leukemia Treatment Combo
16/09	Mendus announces initiation of the DIVA trial
16/09	Mendus AB Announces Initiation Of The Diva Trial Evaluating Vididencel In Combination With Less-Intensive First-Line Treatment In Patients With Acute Myeloid Leukemia
14/09	Mendus draws under the second tranche of the Fenja Capital II A/S loan facility, extending cash runway into the second quarter of 2027
14/09	Mendus AB Draws Under the Second Tranche of the Fenja Capital II A/S Loan Facility, Extending Cash Runway into the Second Quarter of 2027
11/09	Mendus: Positive safety read-out from VITAL-CML trial
11/09	Mendus Reports Positive Read-Out For First Stage Vital-CML Trial
11/09	Mendus Reports 'Positive' Initial Safety Data for Vididencel in Chronic Myeloid Leukemia Trial
11/09	Mendus reports positive read-out for first stage VITAL-CML trial
24/08	Mendus (Q2 Review): Important CML Readout Near
20/08	Mendus AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
20/08	MENDUS AB INTERIM REPORT APRIL– JUNE 2026
13/08	Invitation to presentation of Mendus' second quarter 2026 financial report and business update
31/07	Change in number of shares and votes in Mendus AB (publ)
16/07	Mendus announces collaboration with the South Australian Health and Medical Research Institute (SAHMRI) to support preparation of the VITAL-TFR2 trial in chronic myeloid leukemia (CML)
16/07	Mendus AB and South Australian Health and Medical Research Institute Announce Collaboration to Support Preparation of the Vital-TFR2 Trial in Chronic Myeloid Leukemia
08/07	Mendus Completes First Stage Recruitment for Vididencel Trial
08/07	Mendus reports complete enrollment of the first stage of the VITAL-CML trial
08/07	Mendus AB Reports Complete Enrollment of the First Stage of the Vital-Cml Trial
23/06	Mendus AB (publ) has decided on directed issues of Class C shares and transfer of own ordinary shares
10/06	Mendus AB (publ) repurchases outstanding warrants from Fenja
02/06	Mendus reports long-term progression-free survival associated with broad immune activation in high-risk ovarian cancer